MySmallCap

Small and micro-cap companies are often under-followed and/or under-valued. A Content Carnivores media account to share but never recommend anything.

[MySmallCap @tzack16]

GeoVax Responds to Detection of Clade I #Mpox in North Carolina Wastewater $GOVX https://t.co/d2bfDqt3Kn

[MySmallCap @tzack16]

https://t.co/FrQQIJKwO5

[MySmallCap @tzack16]

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations https://t.co/YnZyOkLJcR $GOVX

[MySmallCap @tzack16]

Utah's robust economy is attracting businesses to the state. Discover why this is the place to thrive. #UtahBusiness #LiveWorkPlay #Utah

https://t.co/lVZosToXIJ

[MySmallCap @tzack16]

RFK Jr. vaccine comments bode well for GeoVax, says Roth Capital. $GOVX #NVAX #multi-antigen

https://t.co/zrmtf42FOB

[MySmallCap @tzack16]

Utah's life sciences sector has experienced consistent growth, fueled by a thriving ecosystem of research institutions, innovative startups, and established companies. Not to mention it's an incredible state to explore! #whyutah #lifesciences

https://t.co/0uhqYwkWOG

[MySmallCap @tzack16]

$GOVX working on addressing the shortage of available #MPOX vaccine. Update from CEO on the disease and the growing need here. https://t.co/d3gWGOcpfe

[MySmallCap @tzack16]

Just Released: 17-page Research Update on biotech company, GeoVax Labs, Inc. (GOVX-NASDAQ) with multiple trials advancing. https://t.co/8rnJhAP2Jz

[MySmallCap @tzack16]

Patients vs. profits: Examining the real cost of the health care industry boom [PODCAST] #healthycarnivor #feedly https://t.co/bX3pMqwM28

[MySmallCap @tzack16]

[Correspondence] Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5 #geovax #feedly https://t.co/T1xKPMcolW

[MySmallCap @tzack16]

“We need roots, not parachutes,” said Fred Hutch Cancer Center infectious disease expert Joshua Hill, MD, who headed the ImmunOptimize scientific committee. #Covid $GOVX https://t.co/jpUfycifzq

[B2i Digital @b2idigital]

We want to welcome @Geovax_News to the @ROTHCapital Partners 3rd Annual Healthcare Opportunities Conference October 9th. See their profile on @B2iDigital at https://t.co/5MsVsQ9rvX

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors. (Source: Company Website 08.06.24)

We look forward to seeing the continued results from David A. Dodd, Arban Domi, Mary Hauser, Susan Hensley, MS, RAC, Kelly McKee, Mark Newman, John Niles, Tom O'Brien, Sreenivasa Rao Oruganti, J. Marc Pipas, MD, Erica Raiden, Mark Reynolds, John W. Sharkey, Jeff Welch, Ashley Zuniga, PhD PMP and the entire GeoVax Labs, Inc. team!

Thanks to the stellar team at ROTH for organizing this conference: Sagar Sheth, Byron Roth, Isabel Mattson-Pain, Amanda McAdams, Otilia "Charo" Montano, Benjamin Bowen, James Antonopoulos, Jason Wittes, Jonathan Aschoff, Ph.D., Boobalan Pachaiyappan, Ph.D. and many others

ROTH is a relationship-driven investment bank headquartered in Newport Beach, CA. For more information on ROTH, please visit https://t.co/f7LaejqxRB.

We hope you’ll be able to attend this pivotal event shaping the future of healthcare innovation.

[MySmallCap @tzack16]

#mpox https://t.co/OX5HHHEpZV

[MySmallCap @tzack16]

Registration Is Now Open for Tribe Public’s Webinar Event
"Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO. https://t.co/4CAPtMD7iG #mpox #vaccine $GOVX

[MySmallCap @tzack16]

#WHO Q&A on #mpox refreshed with latest information https://t.co/yWAWnoyxPZ

[MySmallCap @tzack16]

GeoVax Shares Are Making Big Moves: What's Going On? https://t.co/bzzWFb6rOu

[MySmallCap @tzack16]

So this is huge! No one seems to talk about this company's success and history with HIV years ago. This clinical vaccine is built on a validated platform vs. experimental. $GOVX

[GeoVax, Inc. @Geovax_News]

https://t.co/zxe3NnlXRl

[MySmallCap @tzack16]

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, will present at the 36th Annual Roth Conference in Dana Point, CA, on March 17-19, 2024. https://t.co/1tMDf7J92S

[MySmallCap @tzack16]

Interesting advancement. https://t.co/Q9BOcaZ3Lp

[MySmallCap @tzack16]

GeoVax Announces Gedeptin ® Patient Enrollment Closure for Phase 1/2
Clinical Trial Among Advanced Head and Neck Cancer Patients {hashtag|\#|immunooncology} {hashtag|\#|cancer} {hashtag|\#|headandneckcancer} {hashtag|\#|clinicaltrials}. https://t.co/RGAhXbnIh0